Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions. This retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.
Basal cell carcinoma (BCC) is the most common type of skin cancer in the Netherlands, with its incidence having increased substantially in recent years. ). Over the past decades, non-invasive imaging techniques such as line-field confocal optical coherence tomography (LC-OCT) have emerged as promising alternatives to biopsy for the diagnosis of BCC. When BCC can be diagnosed with high confidence using (LC-)OCT, this may reduce the need for biopsies, accelerate treatment initiation, and improve healthcare efficiency. LC-OCT combines the principles of conventional optical coherence tomography (OCT) and reflectance confocal microscopy (RCM), enabling three-dimensional visualization of the skin at a cellular resolution. Several studies have reported a high specificity of LC-OCT for identifying non-BCC lesions, ranging from 97-99%. In cases where BCC can be diagnosed with high confidence, biopsy may theoretically be omitted, meaning that treatment could be initiated promptly. Reported sensitivities for such "high-confidence" BCC diagnoses range from 95-100%. Although the diagnostic accuracy of LC-OCT has been investigated extensively in research settings, evidence on its real-world clinical performance remains limited. This retrospective study aims to evaluate the clinical utility of LC-OCT in routine dermatological practice.
Study Type
OBSERVATIONAL
Enrollment
297
Maastricht University Medical Center +
Maastricht, Limburg, Netherlands
Tumor free survival
Tumor-free survival rate at 6-12 months follow-up among patients with lesion(s) clinically suspicious for BCC, who were treated based on an LC-OCT-guided diagnosis, with treatment success defined as the absence of residual or recurrent tumor.
Time frame: From enrollment to end of treatment at 6-12 months.
Diagnostic accuracy for BCC detection
Diagnostic parameters (sensitivity, specificity, positive predictive value, negative predictive value, diagnostic odds ratio) will be estimated for diagnosis made by LC-OCT (with histopathology serving as reference standard).
Time frame: From enrollment to end of treatment at 6-12 months.
Treatment strategies
Descriptive evaluation of treatment strategies following LC-OCT-guided diagnosis (ie surgical, topical).
Time frame: From enrollment to end of treatment at 6-12 months.
Number of performed LC-OCT scans
Descriptive evaluation: number of LC-OCT scans performed
Time frame: From enrollment to 6-12 months
Lesion characteristics
Descriptive: lesion characteristics (size, location)
Time frame: At baseline
Proportion of biopsies omitted
Proportion of biopsies omitted
Time frame: From enrollment to end of treatment at 6-12 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.